CORRECTION - FDA GRANTS FAST TRACK DESIGNATION TO SACITUZUMAB GOVITECAN FOR LOCALLY-ADVANCED OR METASTATIC UROTHELIAL CANCERGlobeNewsWire • 04/07/20
FDA GRANTS FAST TRACK DESIGNATION TO SACITUZUMAB GOVITECAN FOR NEOADJUVANT/ADJUVANT METASTATIC UROTHELIAL CANCERGlobeNewsWire • 04/07/20
Immunomedics Halts Phase 3 Trial of Breast Cancer Drug Because of Compelling EfficacyThe Motley Fool • 04/06/20
IMMUNOMEDICS ANNOUNCES EXECUTIVE LEADERSHIP CHANGES AND THE APPOINTMENT OF HAROUT SEMERJIAN AS PRESIDENT AND CHIEF EXECUTIVE OFFICERGlobeNewsWire • 04/06/20
Immunomedics Could Face Second FDA Rejection For Breast Cancer Drug, Goldman Sachs Says In Double DowngradeBenzinga • 04/03/20
IMMUNOMEDICS PROVIDES COVID-19 BUSINESS CONTINUITY UPDATE, AFFIRMS 2020 STRATEGIC PRIORITIES, AND SHARES R&D AND REGULATORY UPDATEGlobeNewsWire • 03/25/20
Immunomedics Competitor Threatens To Leapfrog Approval With Breakthrough Therapy DesignationSeeking Alpha • 01/23/20